44,568 Shares in Journey Medical Co. (NASDAQ:DERM) Acquired by Citadel Advisors LLC

Citadel Advisors LLC bought a new stake in Journey Medical Co. (NASDAQ:DERM - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 44,568 shares of the company's stock, valued at approximately $174,000. Citadel Advisors LLC owned approximately 0.21% of Journey Medical as of its most recent SEC filing.

Separately, Dimensional Fund Advisors LP purchased a new stake in Journey Medical in the 4th quarter valued at $80,000. Institutional investors and hedge funds own 7.25% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on the company. Alliance Global Partners restated a "buy" rating on shares of Journey Medical in a report on Thursday, May 15th. Industrial Alliance Securities set a $10.50 target price on Journey Medical in a report on Thursday, March 27th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $9.88.

Journey Medical Stock Performance

NASDAQ DERM opened at $7.39 on Friday. The stock has a market cap of $172.16 million, a PE ratio of -7.86 and a beta of 0.87. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 1.81. Journey Medical Co. has a twelve month low of $3.54 and a twelve month high of $8.25. The stock has a fifty day simple moving average of $6.92 and a 200-day simple moving average of $5.62.

Journey Medical (NASDAQ:DERM - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.06. The business had revenue of $13.14 million during the quarter, compared to analysts' expectations of $12.05 million. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%. Equities analysts anticipate that Journey Medical Co. will post -1.02 earnings per share for the current year.

Insider Transactions at Journey Medical

In other news, CEO Claude Maraoui sold 4,834 shares of the stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $6.84, for a total transaction of $33,064.56. Following the completion of the transaction, the chief executive officer now directly owns 2,348,313 shares in the company, valued at approximately $16,062,460.92. This represents a 0.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 56,962 shares of company stock worth $299,454. 15.03% of the stock is currently owned by company insiders.

Journey Medical Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.